Prostate Cell News Volume 7.28 | Aug 5 2016

TOP STORY

Analysis of Metastatic Prostate Cancers Suggests Treatment Options

Scientists mapped out abnormal signaling pathways in prostate cancer cells and provided computational approaches to identify individualized targets for therapy. [Press release from Univeristy of California Santa Cruz discussing online prepublication in Cell] Press Release | Abstract | Graphical Abstract

(Ranked by impact factor of the journal)

LABORATORY RESEARCH

Liver Protects Metastatic Prostate Cancer from Induced Death by Activating E-Cadherin Signaling

Investigators reported that membrane surface E-cadherin-expressing prostate cancer cells were resistant to cell death by chemotherapeutic drugs, but E-cadherin null or those expressing E-cadherin only in the cytoplasm were sensitive to death signals and chemotherapies both in vitro and in vivo. [Hepatology] Abstarct | Full Article

Multivalent Peptoid Conjugates Suppress Enzalutamide-Resistant Prostate Cancer Cellular Proliferation

Scientists report the characterization of a multivalent conjugate presenting two bioactive ethisterone ligands arrayed as spatially defined pendant groups on a peptoid oligomer. The conjugate, named Multivalent Peptoid Conjugate 6, suppressed the proliferation of multiple androgen receptor (AR)-expressing prostate cancer cell lines including those that failed to respond to enzalutamide and ARN509. [Cancer Res] Abstract

Metastatic Progression of Prostate Cancer Is Mediated by Autonomous Binding of Galectin-4-O-Glycan to Cancer Cells

Researchers reported spontaneous metastasis of human prostate cancer xenografts which express high levels of galectin-4 along with genetic signatures of EGFR-HER2 signaling and O-glycosylation. [Cancer Res] Abstract

Intra-Tumoral Delivery of Functional ID4 Protein via PCL/Maltodextrin Nano-Particle Inhibits Prostate Cancer Growth

To directly investigate the anti-tumor property, full length human recombinant ID4 encapsulated in biodegradable Polycaprolactone(PCL)/Maltodextrin nano-carrier was delivered to LNCaP cells in which the native ID4 was stably silenced. [Oncotarget] Full Article

A Simple, Rapid, Low-Cost Technique for Naked-Eye Detection of Urine-Isolated TMPRSS2:ERG Gene Fusion RNA

Scientists described a simple, rapid and inexpensive assay which combines robust isothermal amplification technique with a novel visualization method for evaluating urinary TMPRSS2:ERG status at less than USD 5 and with minimal equipment. [Sci Rep] Full Article

The Utility of Urine-Circulating MiRNAs for Detection of Prostate Cancer

Researchers evaluated the utility of urine-circulating microRNAs (miRNAs) as the potential biomarker of prostate cancer, the second most prevalent male cancer worldwide. [Br J Cancer] Full Article

CLINICAL RESEARCH

Radium-223 and Concomitant Therapies in Patients with Metastatic Castration-Resistant Prostate Cancer: An International, Early Access, Open-Label, Single-Arm Phase III b Trial

Scientists investigated safety and overall survival in radium-223 treated patients in an early access program done after the ALSYMPCA study and before regulatory approval of radium-223. [Lancet Oncol] Full Article

Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer

Investigators recently identified one patient showing a response from abiraterone despite expression of AR-V7 in his circulating tumor cells. They precisely assessed the response in a cohort of 21 AR-V7 positive castration-resistant prostate cancer patients who had received therapy with abiraterone or enzalutamide. They detected a subgroup of six AR-V7 positive patients showing benefit from either abiraterone or enzalutamide. [Eur Urol] Abstract

Association of AR-V7 and Prostate Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer

Scientists evaluated the association of prostate specific antigen and androgen receptor splice variant-7 (AR-V7) transcript levels in patients’ blood with time to treatment failure and overall survival with abiraterone acetate and/or enzalutamide treatment in castration resistant prostate cancer patients. [Clin Cancer Res] Abstract

Samarium-153-EDTMP (Quadramet^®) with or without Vaccine in Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase II Trial

Researchers found that no patient in the Sm-153-EDTMP alone arm achieved prostate-specific antigen (PSA) decline > 30% compared with four patients in the combination arm, including three with PSA decline > 50%. [Oncotarget] Full Article

A 3D Toolbox to Enhance Physiological Relevance of Human Tissue Models

The authors discuss the current challenges and future prospects of flow-based organoid models and 3D self-assembling scaffolds. [Trends Biotechnol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Prostate Cancer Foundation Receives More Than $5 Million from the Movember Foundation

The Prostate Cancer Foundation announced five new Movember Foundation-PCF Challenge Awards to advance new treatments and cures for metastatic, lethal prostate cancer. [Prostate Cancer Foundation] Press Release

Damon Runyon Cancer Research Foundation Grants Prestigious Fellowship Awards to 17 Top Young Scientists

The Damon Runyon Cancer Research Foundation named 17 new Damon Runyon Fellows at its spring Fellowship Award Committee review. [Damon Runyon Cancer Research Foundation] Press Release

The FDA Is Prohibited from Going Germline

A potentially renewable provision of the Consolidated Appropriation Act of 2016 forestalling the prospect of human germline modification was signed into law on 18 December 2015. The provision has since been incorporated again into the House and Senate appropriation bills for the fiscal year ending 30 September 2017. [Science] Editorial

US Agency Lifts Ban on Funding Human–Animal Hybrids

Researchers in the United States will soon be able to resume creating chimera-based projects. [Nature] Editorial

Russian Scientists Bracing for Massive Job Losses

Russia’s scientific community is reeling from news that the government plans to fire about 10,000 researchers over the next three years. [ScienceInsider] Editorial

E-mails show how UK physicists were dumped over Brexit

Researchers dropped from EU grant proposal because UK inclusion would ‘compromise’ project. [Nature News] Editorial

NEW European Society for Medical Oncology (ESMO) Asia 2016 Congress
December 16-19, 2016
Singapore, Singapore

Visit our events page to see a complete list of events in the prostate cell community.

NEW Research Scientist – Functional Cancer Genomics (Institute of Oncology Research – Bellinzona)

NEW Senior VP and Director Clinical Research – Oncology (Fred Hutchinson Cancer Research Center)

Assistant/Associate Professor – Genitourinary Cancers (The University of Texas MD Anderson Cancer Center)

Postdoctoral Fellow – Tumor Microenvironment and Cancer Stem Cells (Duke University)

Postdoctoral Fellow – Breast, Prostate and Pancreatic Cancer (MD Anderson Cancer Center)

Postdoctoral Fellow – Epigenetics and Cell Differentiation (Centre National de la Recherche Scientifique)

Associate Editor (PLOS ONE)

Faculty Positions – Cancer Immunology (University of New Mexico Health Science Center)

Postdoctoral Associate – Cancer Research (Sanford Burnham Prebys Medical Discovery Institute)

Postdoctoral Fellow – Cancer Research (University of California – San Francisco)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.